A Study on the Efficacy, Safety, and Mechanism Validation of Telitacicept in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients with Inadequate Response to Rituximab (RTX) (ChiCTR) - Oct 16, 2026 - P4 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University
New P4 trial • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
|